MHRA revokes Novartis’ Adakveo authorisation for sickle cell disease
The UK MHRA has revoked a conditional marketing authorisation for Novartis' Adakveo 10mg/ml to treat sickle cell disease patients.
The UK MHRA has revoked a conditional marketing authorisation for Novartis' Adakveo 10mg/ml to treat sickle cell disease patients.
What's Your Reaction?
